Ethereum's EIP-8297, known as the Partitioned Binary Tree (PBT), passed a key mainnet shadowfork test, marking progress toward a full deployment planned for Q4 2026. The upgrade restructures Ethereum's state data into a simpler binary tree format, aiming to reduce proof sizes and enable future state expiry without downtime. This change supports stateless clients and improves efficiency without altering gas costs or contract operations. Next steps include more tests on other clients and setting an official activation date.
Ethereum's upcoming Partitioned Binary Tree upgrade is noted here alongside Pluang's snapshot of major cryptocurrencies as of Nov 06, 2026 07:02 WIB. Among 50 priced assets, only 3 rose while 46 fell. Stellar (XLM) dropped 8.97% to Rp2.779 with a typical hold time of 85 days and a nearly balanced sell/buy order split. The Graph (GRT) fell 8.48% to Rp342, held typically for 100 days, with a strong 83% sell order activity. Cardano (ADA) declined 8.38% to Rp3.289, held 128 days on average, with 67% sell orders.
Ademi LLP is investigating Strategic Education for potential securities fraud related to inaccurate statements about its financials and business operations, particularly in Australia. This probe follows a more than 20% decline in the company's stock ...
Corporate Insight released research identifying top financial firms leading in customer-facing AI tools, including virtual assistants and AI-powered fintech platforms. Fidelity and Voya lead in retirement plan virtual assistants, while Lively excels ...
Strawberry Fields REIT announced a cash dividend of $0.17 per common share for the fourth quarter of 2026. The dividend will be paid on December 30, 2026, to shareholders recorded by December 16, 2026. The company specializes in owning and leasing he...
Stacks (STX) surged 9.99% to $0.360, leading gains among the 90 largest cryptocurrencies as 77 advanced over 24 hours. Other notable winners included Injective (INJ) up 9.37%, Pearl (PEARL) up 8.29%, Render (RENDER) up 7.26%, and PancakeSwap (CAKE) u...
Perspective Therapeutics presented new Phase 1/2a trial data showing that bamzireotide (VMT-α-NET) achieved durable disease control and promising tumor responses in patients with advanced neuroendocrine tumors expressing SSTR2. Among 57 patients with...
